The Hollow Fiber Model: In Vivo Screening Assay to Speed Up Your Drug Discovery Process
When a drug discovery project enters the phase of in vivo testing many questions arise: “How reliable is our in vitro data? Did we choose the right lead compounds? Which is the best tumor model to use for in vivo efficacy testing?” The Hollow Fiber Model is an in vivo drug screening assay bridging the gap between in vitro and in vivo testing of anticancer agents allowing for rapid answers regarding drug efficacy with simultaneous evaluation of pharmacokinetic and pharmacodynamic parameters.

Click here to access

DIY in Lunatic and Stunner with the Homebrew toolkit
Quantifying biologics often requires many kinds of measurements and a lot of tedious downstream data processing. That can mean time-consuming, hands-on work with different instruments and software before you can get the results you need. Big Lunatic makes protein quantification easy with a wide dynamic range that can measure concentrations from 0.02–200 mg/mL so you can skip the manual dilutions. Maximize your throughput with high-speed UV/Vis spectral analysis with just 2 μL of sample and up to 96 samples at a time. The unique microfluidic circuits molded into Lunatic plates ensure that there’s no cross-contamination or evaporation. Pipet your samples right into Lunatic plates, or hook them up to your favorite automation system if you need higher throughput. Tack on 21 CFR Part 11 compliance if you need it.

Click here to access

Qualifying and Quantifying Plasma Samples with Lunatic
Plasma-based research and biobanking programs have generated abundant interest in cell-free nucleic acid analysis and biomarker discovery. Al­though the quality of plasma can severely impact the success rate of these processes, plasma is typically scored by its perceived color and clarity. Visual assessment of plasma samples can bias their scoring since plasma samples can have the same visual appearance (i.e. color and clarity) yet contain different biological components. Biologi­cally, these parameters are related to hemolysis (pink-red color), icteric serum (orange-dark yellow color), and turbidity (transparent to opaque). Lunatic software can distinguish these samples by quantifying the hemoglobin, bilirubin and protein content, in addition to sample turbidity.

Click here to access

Reliable Osmolality Testing of High Concentration mAb Formulations
Osmolality testing has several unique and essential applications throughout bioprocessing, and new use cases are constantly emerging. As the field of biologics manufacturing matures, osmometers and other analytical devices must keep up and even offer new options to remain valuable. The osmolality of monoclonal antibody (mAb) formulations is typically determined using freezing point depression or vapor pressure osmometers. This paper details an evaluation of the OsmoTECH® XT (freezing point) and Vapro® 5600 (vapor pressure) osmometers as a means of measuring concentrated protein formulations.

Click here to access

Fast & accurate DNA quantification with Lunatic
Fluorescent dye-based assays are one of the predominant methods for quantifying nucleic acids, but they’re bogged down by a lot of steps. If anything goes wrong along the way, the assay needs to be repeated, wasting time and valuable sample. In the typical PicoGreen™ workflow, a DNA standard is serially diluted in the linear range of the fluorescent dye. Then, the standards are diluted in a working solution of the dye to create a standard curve. Finally, the samples are diluted in the working dye solution and the DNA concentration is determined. This process is time-consuming and error-prone, and can also yield inaccurate results if the samples are in an incompatible buffer or saturate the assay.

Click here to access

How to Upgrade from Nector NTI® to Benchling
In the past decade, molecular biology has evolved tremendously, but sequence design software has stagnated. With Vector NTI® set to be officially discontinued by Thermo Fisher, now is the ideal time for life science R&D organizations to digitally transform their molecular biology with a modern, cloud-based platform. This paper outlines the critical software needs for modern molecular biology, and how top-10 pharmaceutical companies have accelerated their research with Benchling's platform-based Molecular Biology application.

Click here to access

Uncle Application Compendium
Uncle is an all-in-one platform that combines fluorescence, static light scattering (SLS) and dynamic light scattering (DLS) detection methods to enable twelve stability applications on a single instrument. These three detection methods make it possible to collect data on thermal melting, aggregation, and sizing with the same set of samples, greatly reducing protein sample volume requirements and the need to use multiple single-measurement instruments to determine stability.

Click here to access

Profiling Oncology Drug Candidates Through Complementary in vitro Assays and in vivo Models to Better Understand Their Potential Clinical Applications
In the lead optimization and candidate selection stages of drug discovery, diverse yet complementary investigations can provide a comprehensive profile of a compound's activity, efficacy, and safety. To obtain as complete a profile as possible, orthogonal approaches–including in vitro binding and biochemical assays, cell-based assays, and in vivo safety and efficacy models–can collectively provide insights into the potential clinical utility of a compound. In this white paper, we describe a profiling strategy that includes both in vitro and in vivo approaches to characterize sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types.

Click here to access

Automated platform buffer screening for multiple proteins on Big Kahuna
The critical process of screening formulation buffers to optimize stability is labor-intensive and time-consuming, which is often a limiting factor in biologics development. The conformational, chemical, and colloidal stability of a protein are strongly influenced by the buffer solution. Altering buffer salts, pH, ionic strength, excipients, and surfactants may increase or decrease the stability of a molecule. To alleviate some of the time requirements in developing a new biologic molecule, a platform buffer screen is typically used to screen common formulation conditions to quickly narrow down optimal buffer conditions. A platform buffer screen analyzes the stability of a new molecule with common buffers, excipients, and surfactants in common pH ranges.

Click here to access

Automated platform buffer screening for multiple proteins on Big Tuna
The critical process of screening formulation buffers to optimize stability is labor-intensive and time-consuming, which is often a limiting factor in biologics development. The conformational, chemical, and colloidal stability of a protein are strongly influenced by the buffer solution. Altering buffer salts, pH, ionic strength, excipients, and surfactants may increase or decrease the stability of a molecule. To alleviate some of the time requirements in developing a new biologic molecule, a platform buffer screen is typically used to screen common formulation conditions to quickly narrow down optimal buffer conditions. A platform buffer screen analyzes the stability of a new molecule with common buffers, excipients, and surfactants in common pH ranges.

Click here to access

Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and Development
Despite substantial efforts utilizing a diverse set of biologic evaluation and high- throughput techniques to select candidates with the best chance of success in preclinical development, the vast majority of biologic drug molecules fail in clinical trials. With most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Here, we discuss the potential for improving identification of potentially successful biologic drugs and de-risking CMC and clinical designs earlier through strategic application of advanced mass spectrometry, and specifically, how detailed assessment of target engagement using HDX-MS and Native-MS analyses may provide understanding to guide biologic development decisions.

Click here to access

High-throughput automated pH measurements for biologics formulations on Big Kahuna and Junior
One of the major challenges in biologic drug development is the need to characterize formulations of drug candidates. One significant bottleneck in this process is pH measurement of formulations. Measuring pH is ubiquitous in the laboratory and critical for preparing buffers, analyzing formulations, monitoring stability, and numerous other applications during formulation development.

Click here to access

Native Analysis of Monoclonal Antibodies by Microchip Capillary Electrophoresis-ESI-MS
The characterization of intact monoclonal antibodies by mass spectrometry is challenging due to the size and complexity of the molecules. The ability to separate charge variants in a separation that is directly coupled to the mass spectrometer greatly improves the MS analysis by minimizing spectral overlap of similar variants, while also providing a charge variant separation which aids in identification of the species. We have previously demonstrated the ability to do such an analysis using microfluidic capillary electrophoresis – ESI-MS under “near native conditions”. This current work extends that capability by operating under fully native conditions which maintain the folded structure of the molecules both during the CE separation and through the ESI transition into the gas phase.

Click here to access

Blast through your problems: ID inorganic and metal particles with LIBS on Hound
The presence of visible and subvisible particulate matter is a risk throughout the development, packaging, and delivery of biologic drugs. There are many sources of potential particulate contamination. Inherent particles, like protein aggregates, come from the formulation itself. Significant contamination risks can come from intrinsic sources such as metal fragments or filter fibers from processing equipment, or glass chips from primary packaging. Extrinsic sources like hair or clothing fibers are also contamination risks. The list of potential contaminant spans protein, organic, inorganic and metal particulates.

Click here to access

Uncle sets a new benchmark for protein characterization
The monoclonal antibody reference material distributed by the National Institute of Standards and Technology (NIST) has been extensively characterized by many researchers, and has become an excellent standard for the biopharmaceutical industry. The large body of data that has been collected and shared on this molecule is invaluable for verifying analytical methods across research and process development groups. In this application note, we describe NISTmAb data collected on the Uncle platform that demonstrates the versatility, reliability and ease-of-use of the instrument.

Click here to access

Cross-functional Collaboration Is Key to Diagnostic Test Commercialization
With advances in molecular and genetic technologies and growing patient demand for more personalized laboratory developed tests (LDTs), the demand for such tests is booming. However, even with these favorable conditions, there are significant challenges in bringing new LDTs to market. With so many new tests being introduced, payers have a hard time wading through the noise to identify those that will be beneficial to their business and their patients. To seize upon new business opportunities and meet market demands for new LDTs as well as take full advantage of the new rates for molecular and genetic lab tests, organizations that provide and develop diagnostic lab tests need strong cross-functional interaction between the revenue cycle and the lab.

Click here to access

Knock out same-time protein concentration and quality with Stunner
Sensitive, quick methods for evaluating protein quality prior to extended characterization studies or assay development save time and precious sample. Uncover more about your samples with Stunner, which combines high-speed UV/Vis analysis with dynamic light scattering (DLS) to measure the concentration and quality of your biologics. Stunner has a wide dynamic range, measuring proteins from 0.02−200 mg/mL, and applies a wavelength-specific correction that provides more accurate values. At the same time concentration is measured, Stunner uses DLS to measure the hydrodynamic diameter of your samples and identify whether aggregates might give cause for concern.

Click here to access

Take a snapshot of your protein quality with Uncle
Evaluating the quality of samples prior to downstream analysis is an integral part of protein characterization workflows. There are many reasons to quickly assess the quality of a protein sample, such as comparing batches of purified material, changing formulation conditions, or checking the integrity of frozen samples after thawing. Even after initial protein stability assessments are performed, there may be instances in which sources of physical or chemical stress, such as oxidation or agitation by sample mixing, can lead to protein unfolding or aggregation prior to downstream analysis. Considering all the ways in which protein quality can be affected by long term storage or handling, performing a fast quality check can save time and ensure sample integrity. Uncle can reliably evaluate the stability of your biologics by using two different measurement modes.

Click here to access

Meet Stunner: The one-shot protein concentration and sizing combo
What if you could get a better read on the quality of your biologics and use less sample at the same time? Stunner takes your protein characterization to the next level by combining high speed UV/Vis spectral analysis with Dynamic Light Scattering (DLS). Using micro-volume Stunner Plates, Stunner measures both the concentration and quality of 96 samples in just 1 hour. The Stunner Plate uses 2 µL of sample and there’s no risk of contamination or evaporation. Measure highly concentrated samples straight up so you don’t introduce error by making manual dilutions. Pipet your samples right into the Stunner Plate or hook it up to your favorite automation system if you need high throughput. Tack on 21 CFR Part 11 compliance if you need it. You choose how to sync up your sample quantity and quality measurements.

Click here to access

Meet Big Tuna: automated, versatile buffer exchange
The critical process of screening formulation buffers to optimize stability is labor intensive and time-consuming, which is often a limiting factor in biologics development. The conformational, chemical, and colloidal stability of a protein are strongly influenced by the buffer solution. Altering buffer salts, pH, ionic strength, excipients, and surfactants may increase or decrease the stability of a molecule. Conventional exchange methods are labor-intensive, prone to inconsistency, and difficult to manage in larger numbers. Existing methods for buffer exchange have various limitations, all of which are exacerbated at higher throughput. Automated buffer exchange systems can enable more uniform sample handling and degrees of process control that are otherwise impractical by manual methods. Big Tuna was developed to address gaps in low-volume, high-throughput buffer exchange.

Click here to access

The New World of GPCR Allosteric Modulation: Another Shot on Goal
Although historically GPCRs have been a rich source of new drug molecules, the discovery of unique drug types for this target class has waned in the last 3 decades. In the same time frame, the emergence of functional screening and the appreciation of the allosteric nature of GPCRs has revitalized the field and led to an explosion of activity that has transformed GPCR discovery.

Click here to access

96 Bottles of Beer: Metabolic Profiling of Spent Growth Media Using Rapid, High Throughput Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry
Bioreactor monitoring is a vital part of quality control and process refinement. There is an ever-growing demand for high throughput analysis methods capable of delivering metabolic profiling data rapidly to the user without the need for extensive sample processing. The presence and concentration of biogenic analytes can often indicate the progress and success or failure of the production process. Beer production is no exception to this as several metabolites have been identified as indicators of beer quality. Here we demonstrate the detection and quantitation of several biogenic amines that have been shown to affect beer flavor.

Click here to access

Using Artificial Intelligence To Determine Patient Response To Immunotherapy
While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient response, but can be limited by the ability to correctly use the test to interpret the complex underlying biology and response profile. New IHC interpretation methods are capturing this biology and defining better patient selection tests, but the interpretations are complicated and hard for pathologists to implement.

Click here to access

Figure out aggregation early: simultaneous, independent measurements of B22 and kD on Uncle
With the trend in biopharmaceuticals to move towards high concentration therapeutics, devel­oping a well-formulated biologic is more import­ant than ever. After ranking and refining down to a set of highly stable molecules, or honing down to good formulations with measurements like Tm and Tagg, the next critical step is reducing the risk of candidates aggregating at high concen­trations. The diffusion interaction parameter (kD) and the second virial coefficient (B22) are both well-established parameters for predicting the colloidal stability and the aggregation propen­sity of proteins. These measurements may be used to confirm stability and minimize the risk of your molecule interacting with itself. With just minutes needed to collect the data, and experi­ments done at lower concentrations, do it earlier in your process and save time and sample.

Click here to access

The Rise of The Biologists: The Changing Face of The Bioinformatics Industry
As in-depth biological knowledge is increasingly a prerequisite for research success, a shortage of bioinformatic skills presents an exciting opportunity for research biologists. In this whitepaper we discuss the context, risk and Thomson Reuter’s first application made specifically for bench biologists.

Click here to access

Turning Data Into Insight: Cognitive Search & Powerful Analytics for Life Sciences
Finding relevant knowledge in the complex and diverse data of Biopharma companies requires cognitive systems using Natural Language Processing (NLP) capable of “understanding” what unstructured data from texts and videos is about. This whitepaper highlights how Cognitive Search and Analytics are key elements for driving innovation, improving the efficiency of research, clinical trials, and regulatory processes.

Click here to access

The insideHPC Guide to Genomics Dell has teamed with Intel® to create innovative
solutions that can accelerate the research, diagnosis and treatment of diseases through personalized medicine. The combination of leading-edge Intel® Xeon® processors and the systems and storage expertise from Dell create a state-of-the-art data center solution that is easy to install, manage and expand as required. Labelled the Dell Genomic Data Analysis Platform (GDAP), this solution is designed to achieve fast results with maximum efficiency. The solution is architected to solve a number of customer challenges, including the perception that implementation must be large-scale in nature, compliance, security and clinician uses. Read this white paper to learn more.

Click here to access

Enabling Data Transfer Management and Sharing In the Era of Genomic Medicine
As sequencing technologies continue to evolve and genomic data makes its way into clinical use and medical practice, a momentous challenge arises−how to cope with the rapidly increasing volume of complex data. Issues such as data storage, access, transfer, sharing, security, and analysis must be resolved to enable the new era of genomic medicine.

Click here to access

Turning Genomics Data into Practical Insight Given
the prodigious output of Next Generation Sequencing (NGS) instruments, high performance computing (HPC) has become the only practical way to sift through the data to discover useful insight, a point made clearly in a recent Nature Perspective, “The major bottleneck in genome sequencing is no longer data generation — the computational challenges around data analysis, display and integration are now rate limiting … Adequate computational infrastructure … including sufficient storage and processing capacity to accommodate and analyze large, complex data [is needed].”

Click here to access

Instrument Utilization: The Missing Piece of Asset Management
Instrument Utilization is a critical component of modern lab operations. As research and lab workflows evolve, the use of different instrumentation ebbs and flows. These changes are hard to predict and quantify but have substantial impact on the efficiency of your lab. In this white paper you will get an overview of typical strategies for measuring utilization and learn about new technology emerging in the space.

Click here to access

Regulation of mobile medical apps
The FDA and European regulators encourage the development of mobile medical apps to enable patients to manage their own health and wellbeing, yet the regulatory status of a smartphone remains a source of confusion. Novarum DX, has produced a whitepaper which provides guidance on the regulation of mobile medical apps.

Click here to access

Improving Charge Variant Analysis with Maurice Native Fluorescence
Most post-translational and degradation events affect the biological activity of therapeutic proteins, making charge heterogeneity analysis a critical quality attribute for molecule characterization. Both iCE280 and iCE3 use protein absorption at 280 nm to monitor charge heterogeneity, and now Maurice adds native fluorescence detection to greatly increase cIEF capabilities. Maurice’s native fluorescence detection for cIEF works by measuring the fluorescence emission of tryptophan’s aromatic group. It’s labelfree so you’re not wasting time optimizing protein labeling or dealing with the background noise when label unconjugates from your protein. Baselines are significantly cleaner and less sensitive to ampholyte interference, giving you more options when optimizing your pH gradient.

Click here to access

See What Light Obscuration Misses with Micro-Flow Imaging
Subvisible particles are a critical quality attribute for pharmaceutical products as protein aggregates can elicit an immunogenic response that affects the therapeutic's efficacy.¹Regulatory agencies require a full analysis of any particles present in a therapeutic product, including quantitative measurements of size and count and information on the type of the particles. Compendial methods like Light Obscuration (LO) don’t give you complete profiles due to gaps in their analysis, creating more risk during QC or when you need to file New Drug Applications (NDAs). Micro-Flow Imaging (MFI®) on the MFI 5000 Series system fills in those gaps because it sees particles LO can’t — making it the perfect complement for your regulatory submissions. The system classifies proteins and non-protein particles and gives you direct, image-based detection of size, count and shape for sub-visible particles between 1-300 microns in solution.In this white paper, we’ll highlight the differences between MFI and LO using published literature to help you learn more about how MFI can improve your particle analysis.

Click here to access

High Fidelity Detection of Endogenous PD-L1 at Low Picogram Levels with Simple Plex Assays
Enlisting a patient’s own immune system to fight cancer has been a longstanding dream for cancer biologists. Immune checkpoint inhibitors targeting molecules like programmed death-ligand 1 (PD-L1) help make the dream a reality and are now transforming today’s cancer therapy. PD-L1 therapy has gained interest as a paradigm shifting approach to cancer treatment due to its durable effects, and its ability to target a broad range of cancers1,2,3 with manageable toxicity compared to traditional chemotherapy. In this application note, we compare endogenous PD-L1 detection in PTEN mutated glioma cell supernatant and blood cells using the Simple Plex assay and a commercially available sandwich ELISA assay to demonstrate data equivalency and the added sensitivity you’ll get with a Simple Plex assay.

Click here to access

5 Ways to Manage the Rising Costs of Benefits for small and medium-sized businesses
A robust benefits package can be the difference between a talented superstar choosing to work with you as opposed to a larger, more establishedcompetitor. But with the cost of benefits rising each year, providing a benefits package that helps you attract, retain, and motivate talented peoplegets harder all the time.With knowledge and planning, you can create a win-win situation for yourself and your employees. You can use benefits to meet the needs of yourworkforce and successfully compete for top talent. As a business owner, it’s important to be aware of the ways you can manage costs and attract tophires.

Click here to access

Turning Text into Insight: Text Mining in the Life Sciences
Given the volume of scientific literature and the pace at which it is published, it’s neither feasible nor cost-effective for researchers to read and analyze this material one article at a time. Life science researchers use text mining tools to analyze massive amounts of information quickly to extract data, assertions, and facts. Read this paper to learn about text mining and three approaches to maximize its efficiency and potential for discovery.

Click here to access

Enabling Data Transfer Management and Sharing In the Era of Genomic Medicine
As sequencing technologies continue to evolve and genomic data makes its way into clinical use and medical practice, a momentous challenge arises−how to cope with the rapidly increasing volume of complex data. Issues such as data storage, access, transfer, sharing, security, and analysis must be resolved to enable the new era of genomic medicine.

Click here to access

Turning Text into Insight: Text Mining in the Life Sciences
Given the volume of scientific literature and the pace at which it is published, it’s neither feasible nor cost-effective for researchers to read and analyze this material one article at a time. Life science researchers use text mining tools to analyze massive amounts of information quickly to extract data, assertions, and facts. Read this paper to learn about text mining and three approaches to maximize its efficiency and potential for discovery.

Click here to access

The insideHPC Guide to Genomics Dell has teamed with Intel® to create innovative
solutions that can accelerate the research, diagnosis and treatment of diseases through personalized medicine. The combination of leading-edge Intel® Xeon® processors and the systems and storage expertise from Dell create a state-of-the-art data center solution that is easy to install, manage and expand as required. Labelled the Dell Genomic Data Analysis Platform (GDAP), this solution is designed to achieve fast results with maximum efficiency. The solution is architected to solve a number of customer challenges, including the perception that implementation must be large-scale in nature, compliance, security and clinician uses. Read this white paper to learn more.

Click here to access

Turning Genomics Data into Practical Insight Given
the prodigious output of Next Generation Sequencing (NGS) instruments, high performance computing (HPC) has become the only practical way to sift through the data to discover useful insight, a point made clearly in a recent Nature Perspective, “The major bottleneck in genome sequencing is no longer data generation — the computational challenges around data analysis, display and integration are now rate limiting … Adequate computational infrastructure … including sufficient storage and processing capacity to accommodate and analyze large, complex data [is needed].”

Click here to access

Turning Data Into Insight: Cognitive Search & Powerful Analytics for Life Sciences
Finding relevant knowledge in the complex and diverse data of Biopharma companies requires cognitive systems using Natural Language Processing (NLP) capable of “understanding” what unstructured data from texts and videos is about. This whitepaper highlights how Cognitive Search and Analytics are key elements for driving innovation, improving the efficiency of research, clinical trials, and regulatory processes.

Click here to access

The Rise of The Biologists: The Changing Face of The Bioinformatics Industry
As in-depth biological knowledge is increasingly a prerequisite for research success, a shortage of bioinformatic skills presents an exciting opportunity for research biologists. In this whitepaper we discuss the context, risk and Thomson Reuter’s first application made specifically for bench biologists.

Click here to access

Instrument Utilization: The Missing Piece of Asset Management
Instrument Utilization is a critical component of modern lab operations. As research and lab workflows evolve, the use of different instrumentation ebbs and flows. These changes are hard to predict and quantify but have substantial impact on the efficiency of your lab. In this white paper you will get an overview of typical strategies for measuring utilization and learn about new technology emerging in the space.

Click here to access

5 Ways to Manage the Rising Costs of Benefits for small and medium-sized businesses
A robust benefits package can be the difference between a talented superstar choosing to work with you as opposed to a larger, more establishedcompetitor. But with the cost of benefits rising each year, providing a benefits package that helps you attract, retain, and motivate talented peoplegets harder all the time.With knowledge and planning, you can create a win-win situation for yourself and your employees. You can use benefits to meet the needs of yourworkforce and successfully compete for top talent. As a business owner, it’s important to be aware of the ways you can manage costs and attract tophires.

Click here to access

Getting the Whole Picture for Immuno-Oncology Therapies
Diagnostics that identify the targets of a drug have been a cornerstone in conveying the value of precision medicine approaches. In the past, patient selection for classic targeted therapeutics was based on a single biomarker using a single assay involving a single methodology (e.g., HercepTest™); however, a lot has changed since the approval of Herceptin® nearly 20 years ago. The first-generation immune checkpoint inhibitors such as YERVOY®, OPDIVO®, KEYTRUDA®, TECENTRIQ®, and BAVENCIO® have transformed the way we approach cancer therapy. Now, the profile of the patient’s immune system and its interaction with the tumor is considered as much as the target of the therapy itself.

Click here to access

Why Declining Returns on R&D Demand Better Workflow Efficiencies
Ask ten people to define innovation and it’s likely that you’ll get ten different answers. Most would agree, though, that it includes some combination of a good ideas, solves a real problem, is executed well, and adds value to the company. But while it may seem intuitive that investments in R&D lead to greater profits, it’s really not all that cut and dried. Not all R&D investments are created equal, and they certainly don’t all produce the same results. For example, R&D activities may not be focused on the right problems, and even when they are, they may not, for a variety of reasons, pan out in the profitability department. And then there’s competition.

Click here to access

Acquiring Scientific Content
SO CLOSE AND YET SO FAR Is that how many documents seem to you? Indeed, getting what you want—when, where, and how you want it—can be a real uphill battle. It’s a process that can be fraught with difficulties, not the least of which includes the overwhelming volume and complexity of content and the myriad ways of accessing and managing it. And that’s true for everyone involved, from the content licensors to the aggregators to the librarians to the end users.

Click here to access

Reducing Cycle Time with Digital Transaction Management
This eBook provides best practices to drive digital adoption in life sciences, including how you can: Reduce Cycle Time, Improve Trial Enrollment and Informed Consents, Simplify Operations & Approvals.

Click here to access

DocuSign Life Science Solutions for Regulated Life Science Operations
The pressure has never been greater for life science organizations to shorten the development cycle for new drugs and devices — and to do so while cutting costs and complying with industry regulations like 21 CFR Part 11 and Annex 11. DocuSign makes it easier and more efficient for you to adopt digital approvals, agreements and processes for regulated life science use cases. To fuel your digital success, we have outlined DocuSign’s options to help you implement e-signature and digital platform solutions while adhering to life science regulations: DocuSign Life Sciences Module, DocuSign Signature Appliance, Third Party Industry Credentials and Process Validation

Click here to access

Acquiring Scientific Content: How Hard Can It Be?
SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs.

Download it here and learn how to:

• Avoid busting the budget on expensive subscription access
• Acquire even the most elusive content with equal ease
• Slash delivery turnaround time from days to minutes

Click here to access

IC3D — “Finding your Needle in a Haystack”
In healthcare today, better and faster diagnostics lead to better treatment and outcomes for patients. The challenge in many situations is that the existing tools are simply lacking in terms of speed, sensitivity, and accuracy. This problem is even more pronounced when one needs to “find that small needle in a haystack” and assess rare targets (specific cells, proteins, DNA, RNA, etc.) quickly and accurately in complex patient samples (whole blood, plasma, urine, etc.). A similar problem also persists in other industries such as pharmaceutical manufacturing and food safety, where a rapid test for biological testing (e.g., microbial contamination) would save time, money, and improve safety.
Click here to access

IC3D — “Droplet by Droplet” to Single Target Sensitivity
The most critical challenge of assessing rare targets in large-size samples is how to overcome the problems of (1) finding the needle in a haystack, and (2) extremely low signal-to-noise ratio. With the exceedingly low abundance of the targets against the immense “swamp” of the background, any faint signal by the targets is probably swamped by the background chatter. In the IC3D technology, we have two “magic tricks” working in tandem to solve this long-standing challenge.
Click here to access

Drug Discovery Toolbox: Summary of results from peer reviewed publications, key features and technology
The audience will learn how this device enables implementation of infusion protocols to reliably and precisely achieve the desired exposure profiles (shapes and timing) with low degree of invasiveness. All summarized from peer reviewed publications and PhD thesis. Targeted and systemic delivery using catheters (iv, sc, intrathecal and ip) and brain infusion kits with chrono-release, intermittent and continuous drug delivery examples. Results requiring frequent refilling, every 2-3 days will also be presented.
Click here to access

AlliedMercury Innovative Supply Chain Partners Are Good Medicine
In this white paper we’ll explore how a customized and integrated supply-chain creates both significant business advantages and superior results. Making sure that your products reach the right people on time is a mission-critical essential in today’s world. There is no room for error in any part of the process. Your long-term viability depends on it.
Click here to access  

Wiley Chem Planner Synthesis Solved
In this case study, Wiley ChemPlanner was applied to help a chemist identify alternative and shorter synthetic routes to target molecules. Options that were not known to the chemist and would likely not have been identified by searching the literature with traditional search tools were found. ChemPlanner thus helped the chemist to increase the efficiency of the synthesis development process by reducing the time and resources spent.
Click here to access  

Syngeneic mouse models as a tool to study immune modulatory effects of cancer therapeutics
Every cancer treatment has the potential to induce a stimulatory or inhibitory effect on the immune response to a tumor. Scientific knowledge about the significance of the immune system for tumor eradication during conventional treatment is growing quickly, and an increasing number of immune-modulating drugs are entering clinical trials for cancer treatment.
Click here to access  

Better Antibody Screening Whitepaper
Learn how adopting High Throughput Flow technology has enabled leading biotechnology companies to improve their antibody screening.
Click here to access  

Next Generation Phenotypic Screening Whitepaper
Learn why some large pharmas are incorporating phenotypic screening as part of their drug discovery strategy and what technology challenges still remain.
Click here to access  

Developing a Bioformulation Stability Profile
Here we describe the development of a bioformulation stability profile, derived from sub-micron light scattering and micro-capillary viscometry to assess the stability of bioformulations.
Click here to access  

Best Ultrasensitive Tau Assay Enables Quantification of Neuronal Biomarker
It has been well established that the neuronal protein tau has an important role in the diagnosis of Alzheimer's disease (AD).
Click here to access

Lab Workstation Automation
“You have to walk before you can run.” You’ve heard it in other contexts, but is it true in laboratory automation? Our experience indicates that it is. We’ve also learned that trying to automate everything at once is a prescription for disaster. Like the human progression from crawling to walking to running, labs that choose to automate do it most successfully in a logical sequence of steps, or phases, each one building on the foundation of the last.
Click here to access  

Fast and Accurate Sample ID in the Lab
Laboratories—whether clinical, analytical, or pure research—can scarcely automate today without barcodes. While other technologies may someday offer more cost-effective ID techniques, barcodes are generally the best technology for positive sample identification within modern labs.
Click here to access

Scientific Principle of Simoa Technology
Quanterix has developed an approach for detecting thousands of single protein molecules simultaneously.
Click here to access  

Best Practices in Hiring for Diagnostic & Laboratory Testing Industries
If you are responsible for hiring, you are in the success business. And when the people you hire are successful it is likely that your company will be successful too.
Click here to access  

Enabling Data Transfer Management and Sharing In the Era of Genomic Medicine
As sequencing technologies continue to evolve and genomic data makes its way into clinical use and medical practice, a momentous challenge arises−how to cope with the rapidly increasing volume of complex data. Issues such as data storage, access, transfer, sharing, security, and analysis must be resolved to enable the new era of genomic medicine.
Click here to access  

Enterprise Informatics: Key to Precision Medicine, Scientific Breakthroughs, and Competitive Advantage
Given their level of investment in data and data management systems, healthcare delivery and life sciences organizations should be deriving considerable value from their data. Yet most organizations have little to show for their effort; the capabilities of their systems are highly compromised, and the practice of precise, evidence-based medicine remains elusive. The fact that these institutions have spent many years collecting data and building infrastructure for so little return has, for many, become “the elephant in the room”—a painfully obvious and uncomfortable topic of conversation.
Click here to access